Immunology

Immune Checkpoint Blockade

Anti-PD-1/PD-L1
Pembrolizumab
Nivolumab
Cemiplimab
Sintilimab
Spartalizumab
Atezolizumab
Durvalumab
Avelumab
Anti-CTLA-4
Ipilimumab
Tremelimumab
Zalifrelimab
Quavonlimab
Anti-LAG-3
Relatlimab
Anti-VISTA
CA-170
NSC622608
Anti-CD47
Magrolimab
Anti-CD47
Anti-TIM-3
Sabatolimab
Cobolimab
Anti-TIGIT
Tiragolumab
Vibostolimab
Anti-B7-H3 (CD276)
Enoblituzumab
Omburtamab
Anti-BTLA (CD272)
Icatolimab

Immunosuppressants

Cytotoxic Molecules [13]
Cyclophosphamide
Busulfan
Cisplatin
Ifosfamide
Thiotepa
Antimetabolites
Mycophenolate mofetil
Azathioprine
Calcineurin Inhibitors
Cyclosporine
Cyclosporin A
Tacrolimus
Pimecrolimus
Immunoproteasome Inhibitors
Bortezomib
Carfilzomib
Sotrastaurin
Immunosuppressive Antibodies
Tocilizumab
Rituximab
Belimumab
Eculizumab
Obinutuzumab
Sutimlimab
Siplizumab

References

  • https://pubs.acs.org/doi/abs/10.1021/acs.accounts.0c00337
  • https://pubmed.ncbi.nlm.nih.gov/32958760/
  • https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0900-3
  • https://pubmed.ncbi.nlm.nih.gov/32571374/
  • https://www.sciencedirect.com/science/article/abs/pii/S1043661818320668
  • https://academic.oup.com/jleukbio/article-abstract/111/6/1269/6885169?login=false
  • https://www.nature.com/articles/s41417-023-00638-7
  • https://www.sciencedirect.com/science/article/abs/pii/S1044579X19304067
  • https://www.mdpi.com/2072-6694/11/12/2002
  • https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12946
  • https://doi.org/10.1016/B978-0-7020-6896-6.00077-6
  • https://pubmed.ncbi.nlm.nih.gov/29988701/
  • https://pubmed.ncbi.nlm.nih.gov/34415233/
  • https://www.mdpi.com/1420-3049/27/2/555
  • https://link.springer.com/protocol/10.1007/978-1-0716-1892-9_8